NAUT logo

NAUT

Nautilus Biotechnology Inc.

$1.85
-$0.13(-6.57%)
48
Overall
60
Value
58
Tech
26
Quality
Market Cap
$194.51M
Volume
247.13K
52W Range
$0.62 - $2.54
Target Price
$2.50

Company Overview

Mkt Cap$194.51MPrice$1.85
Volume247.13KChange-6.57%
P/E Ratio-2.7Open$2.03
Revenue--Prev Close$1.98
Net Income$-70.8M52W Range$0.62 - $2.54
Div YieldN/ATarget$2.50
Overall48Value60
Quality26Technical58

No chart data available

About Nautilus Biotechnology Inc.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system designed to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which are comprised of sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

Sector: Professional, Scientific, and Technical Services
Industry: Testing Laboratories

Latest News

Guggenheim Sticks to Their Buy Rating for Nautilus Biotechnolgy (NAUT)

In a report released today, from Guggenheim reiterated a Buy rating on Nautilus Biotechnolgy, with a price target of $2.50. The word on The Street ...

TipRanks Auto-Generated Intelligence Newsdesk5 days ago
ABCD
1SymbolPriceChangeVol
2NAUT$1.85-6.6%247.13K
3
4
5
6

Get Nautilus Biotechnology Inc. Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.